BOSTON, March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointments of Julie Cherrington, Ph.D. and Alan Sandler, M.D., to its Board of Directors. "We are thrilled to welcome Julie and Alan as Elevation Oncology's newest directors," said Steve Elms, Chairman of Elevation Oncolog ...

BOSTON, Feb. 28, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that members of management will participate in upcoming investor conferences in March: TD Cowen 44th Annual Health Care Conference. Fireside chat on Wednesday, March 6, 2024 at 10:30 AM ET in Boston, MA. Leerink Global Biopharm ...

公司动态 - Elevation Oncology宣布在日本扩大了正在进行的Phase 1临床试验，首位患者接受了EO-3021的剂量[1] - Elevation Oncology正在评估EO-3021在Phase 1研究中的表现，该研究招募了患有Claudin 18.2表达的晚期、不可切除或转移性实体瘤的患者[4] 产品介绍 - EO-3021是一种临床阶段的抗体药物结合物（ADC），具有最佳潜力，可靶向Claudin 18.2[3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40523 Elevation Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 84-1771427 (State or other j ...

公司概况 - 公司是一家专注于发现和开发选择性癌症治疗药物的创新肿瘤公司[104] 产品信息 - 公司的主力产品候选药物EO-3021是一种抗体药物结合物（ADC），旨在靶向克劳丁18.2，目前在中国进行临床试验[105] - 公司计划在2023年下半年在美国启动EO-3021的临床试验[106] 合作与协议 - 公司与CSPC签署了许可协议，支付了2700万美元的一次性前期付款，未来可能支付高达10亿美元的商业里程碑款项[109] 临床试验结果 - 在中国进行的SYSA1801（EO-3021）临床试验的关键发现包括：33名患有克劳丁18.2表达的难治性/耐药性实体瘤患者中，胃癌患者占78.8%，胰腺癌患者占21.2%[110] - 在数据截止日期为2022年11月5日时，21名患者（胃癌17例，胰腺癌4例）根据RECIST v1.1评估，胃癌的客观缓解率为47.1%，疾病控制率为64.7%[113] - 与标准化疗相比，EO-3021在胃癌和胰腺癌的体内模型中表现更好[121] 财务状况 - 公司通过公开发行筹集了4650万美元的净收益[124] - 公司预计现金、现金等价物和可交易证券107.9万美元将能够满足资本需求至2025年下半年[131] 研发费用 - 研发费用在2023年第二季度为6,029千美元，较2022年同期的16,300千美元减少了10,271千美元[144] - 公司的研发费用主要用于制造Seribantumab的临床供应，2023年第二季度为6,029千美元[4] - 公司的研发费用主要用于推进EO-3021的临床试验，2023年第二季度有0.6百万美元的增加[4] 费用管理 - 2023年第二季度，公司的总营运费用为9,834千美元，较2022年同期的20,113千美元减少了10,279千美元[144] - 2023年第二季度，公司的研发费用为6,029千美元，较2022年同期的16,300千美元减少了10,271千美元[144] - 2023年第二季度，公司的管理费用为3,805千美元，与2022年同期持平[144] - 公司预计未来的管理费用将增加，主要用于支持研发活动和产品候选药物的开发[142] 资金需求与融资计划 - 未来资金需求将主要用于推进EO-3021的临床试验和寻找新的产品候选药物[164] - 公司预计现有的现金、现金等价物和可市场化证券107.9百万美元足以支持资金需求至2025年下半年[157] - 公司未来的资本需求将取决于多个因素，包括产品候选药物的临床试验进展、COVID-19疫情对临床试验招募的影响、未来产品候选药物的开发和获得监管批准的成本、与第三方制造商达成协议的范围和成本、组织扩张的成本等[167] - 公司预计在成功完成临床开发并获得监管批准之前不会从产品销售中产生收入，预计将面临与支持产品销售、营销和分销相关的重大费用[168] - 公司预计在未来通过公开或私人股权或债务融资或其他来源融资，可能包括与第三方的合作，但可能无法获得有利的额外融资，这可能会迫使公司推迟、减少或取消研发计划、商业化计划或其他运营[169]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40523 Elevation Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 84-1771427 (State or other juris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-40523 ELEVATION ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 84-1771427 (State of Other Jurisdiction of incor ...

Corporate Overview SEPTEMBER 2021 Forward Looking Statements These slides contain forward-looking statements and information relating to Elevation Oncology, Inc. within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on forward-looking statements, as these statements are based upon our current expectations, forecasts, and assumptions and are subject to significant risks and uncertainties. Any statem ...